報價延遲最少15分鐘:2025/01/11 17:57 EST
|
|
|
|
|
||||||||||||
|
|
|
|
|
21.15 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-1.65/-1.97
|
|
企業價值
784.80M
|
| 資產負債 |
|
每股賬面淨值
2.50
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/01/11 17:57 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Oculis Holding AG is a global biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. |